Education
About Us
Working with TipRanks
Follow Us
LAVA Therapeutics (LVTX)
NASDAQ:LVTX
LVTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.85 - $4.21
Previous CloseN/A
Volume31.56K
Average Volume (3M)771.39K
Market Cap
$33.92M
Enterprise Value-$28.03M
Total Cash (Recent Filing)-$6.54M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Mar 20, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding26,292,187
10 Day Avg. Volume2,252,130
30 Day Avg. Volume771,387
Standard Deviation0.27
R-Squared0.00976
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.01
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.53
Enterprise Value/Ebitda1.02
Forecast
1Y Price Target
$1.67Price Target Upside29.46% Upside
Rating ConsensusHold
Number of Analyst Covering4
---
LAVA Therapeutics News
PremiumCompany Announcements
LAVA Therapeutics Announces Restructuring Plan for 2025
PremiumCompany Announcements
LAVA Therapeutics to Transition to U.S. Domestic Issuer
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentLAVA-1266 has the potential to be a first-in-class γδ T cell engager for the treatment of refractory and relapsed AML.
PartnershipsLava continues to support ongoing partnerships with Pfizer and JNJ.
Bears Say
Platform UncertaintyUncertainty surrounds the Vδ2 TCE platform's effectiveness due to the discontinuation, raising questions about its viability beyond program-specific issues.
---
Ownership Overview
―
Insiders
2.98% Mutual Funds
23.53% Other Institutional Investors
73.50% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LVTX FAQ
What was LAVA Therapeutics’s price range in the past 12 months?
LAVA Therapeutics lowest stock price was $0.85 and its highest was $4.21 in the past 12 months.
What is LAVA Therapeutics’s market cap?
LAVA Therapeutics’s market cap is $33.92M.
When is LAVA Therapeutics’s upcoming earnings report date?
LAVA Therapeutics’s upcoming earnings report date is Mar 20, 2025 which is in 17 days.
How were LAVA Therapeutics’s earnings last quarter?
LAVA Therapeutics released its earnings results on Dec 10, 2024. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.33 by -$0.13.
Is LAVA Therapeutics overvalued?
According to Wall Street analysts LAVA Therapeutics’s price is currently Undervalued.
Does LAVA Therapeutics pay dividends?
LAVA Therapeutics does not currently pay dividends.
What is LAVA Therapeutics’s EPS estimate?
LAVA Therapeutics’s EPS estimate is -0.3.
How many shares outstanding does LAVA Therapeutics have?
LAVA Therapeutics has 26,292,187 shares outstanding.
What happened to LAVA Therapeutics’s price movement after its last earnings report?
LAVA Therapeutics reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.33. Following the earnings report the stock price went down -23.56%.
Which hedge fund is a major shareholder of LAVA Therapeutics?
Currently, no hedge funds are holding shares in LVTX
---
LAVA Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.67 (29.46% Upside)
$1.67 (29.46% Upside)
Hedge Fund Trend
Decreased
By 87.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.7%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.27%
12-Months-Change
Fundamentals
Return on Equity
-63.12%
Trailing 12-Months
Asset Growth
-24.92%
Trailing 12-Months
Company Description
LAVA Therapeutics
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.
---
LVTX Stock 12 Month Forecast
Average Price Target
$1.67
▲(29.46% Upside)
Technical Analysis
Fate Therapeutics
―
Iovance Biotherapeutics
―
Affimed
―
Adaptimmune Therapeutics
―
Immatics
―
Best Analysts Covering LVTX
1 Year
1 Year Success Rate
2/4 ratings generated profit
1 Year Average Return
-6.93%
reiterated a buy rating 7 months ago
Copying Roger Song's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -6.93% per trade.
---